Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
http://www.reportlinker.com/p0739405/Fabry's-Disease-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global Fabry's Disease Therapeutics market. The report identifies the key trends shaping and driving the global Fabry's Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Fabry's Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Fabry's Disease Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Fabry's Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Fabry's Disease Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Fabry's Disease Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Fabry's Disease Therapeutics market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Fabry's Disease Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Fabry's Disease Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Fabry's Disease Therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Fabry's Disease Therapeutics - Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology 8
2.4 Symptoms 9
2.5 Diagnosis 11
2.6 Pathophysiology 12
2.7 Treatment and Management Pattern 13
2.8 GlobalData Pipeline Report Guidance 13
3 Fabry's DiseaseTherapeutics - Market Characterization 14
3.1 Fabry's Disease Therapeutics Market Size (2005-2010) - Global 14
3.2 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Global 16
3.3 Fabry's Disease Therapeutics Market Size (2005-2010) - The US 17
3.4 Fabry's Disease Therapeutics Market Forecast (2010-2018) - The US 18
3.5 Fabry's Disease Therapeutics Market Size (2005-2010) - France 19
3.6 Fabry's Disease Therapeutics Market Forecast (2010-2018) - France 20
3.7 Fabry's Disease Therapeutics Market Size (2005-2010) - Germany 21
3.8 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Germany 22
3.9 Fabry's Disease Therapeutics Market Size (2005-2010) - Italy 23
3.10 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Italy 24
3.11 Fabry's Disease Therapeutics Market Size (2005-2010) - Spain 25
3.12 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Spain 26
3.13 Fabry's Disease Therapeutics Market Size (2005-2010) - The UK 27
3.14 Fabry's Disease Therapeutics Market Forecast (2010-2018) - The UK 28
3.15 Fabry's Disease Therapeutics Market Size (2005-2010) - Japan 29
3.16 Fabry's Disease Therapeutics Market Forecast (2010-2018) - Japan 30
3.17 Drivers and Barriers for the Fabry's Disease Therapeutics Market 31
3.17.1 Drivers for the Fabry's Disease Therapeutics Market 31
3.17.2 Barriers for the Fabry's Disease Therapeutics Market 32
3.18 Opportunity and Unmet Need 32
3.19 Key Takeaway 33
4 Fabry's Disease Therapeutics - Competitive Assessment 34
4.1 Overview 34
4.2 Strategic Competitor Assessment 34
4.3 Product Profile for Major Marketed Products in the Fabry's Disease Therapeutics Market 35
4.3.1 Fabrazyme (agalsidase beta) 35
4.3.2 Replagal (agalsidase alfa) 37
4.4 Key Takeaway 39
5 Fabry's Disease Therapeutics - Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Fabry's Disease - Pipeline Analysis by Phase of Development 40
5.3.1 Fabry's Disease - Phase III Pipeline 40
5.3.2 Fabry's Disease - Preclinical Pipeline 40
5.4 Fabry's Disease - Pipeline by Mechanism of Action 41
5.5 Technology Trends Analytical Framework 42
5.6 Most Promising Drug Profiles 43
5.6.1 Amigal (AT1001, migalastat hydrochloride) 43
5.6.2 Amigal (migalastat hydrochloride) + Enzyme Replacement Therapy 43
5.7 Key Takeaway 44
6 Fabry's Disease Therapeutics - Clinical Trials Mapping 45
6.1 Clinical Trials by Region and Country 45
6.2 Clinical Trials by Phase of Clinical Development 46
6.3 Clinical Trials by Trial Status 47
6.4 Clinical Trials by Sponsors 48
6.5 Top Companies Participating in Fabry's Disease Clinical Trials 50
7 Fabry's Disease Therapeutics - Strategic Assessment 51
7.1 Key Events Impacting the Future Market 51
7.2 Future Market Competition Scenario 52
8 Fabry's Disease Therapeutics - Future Players 54
8.1 Introduction 54
8.2 Company Profiles 55
8.2.1 GlaxoSmithKline 55
8.2.2 Amicus 56
8.3 Details of Other Companies in the Pipeline 58
8.4 Key Takeaway 59
9 Fabry's Disease Therapeutics - Licensing and Partnership Deals 60
10 Fabry's Disease Therapeutics - Appendix 61
10.1 Definitions 61
10.2 Acronyms 61
10.3 Research Methodology 62
10.3.1 Coverage 62
10.3.2 Secondary Research 62
10.3.3 Forecasting 63
10.3.4 Primary Research 66
10.3.5 Expert Panel Validation 66
10.4 Contact Us 66
10.5 Disclaimer 66
10.6 Bibliography 67
List of Tables
Table 1: Fabry's Disease Market, Global, Revenue ($m), 2005-2010 15
Table 2: Fabry's Disease Market, Global, Forecast ($m), 2010-2018 16
Table 3: Fabry's Disease Market, The US, Revenue ($m), 2005-2010 17
Table 4: Fabry's Disease Market, The US, Forecast ($m), 2010-2018 18
Table 5: Fabry's Disease Market, France, Revenue ($m), 2005-2010 19
Table 6: Fabry's Disease Market, France, Forecast ($m), 2010-2018 20
Table 7: Fabry's Disease Market, Germany, Revenue ($m), 2005-2010 21
Table 8: Fabry's Disease Market, Germany, Forecast ($m), 2010-2018 22
Table 9: Fabry's Disease Market, Italy, Revenue ($m), 2005-2010 23
Table 10: Fabry's Disease Market, Italy, Forecast ($m), 2010-2018 24
Table 11: Fabry's Disease Market, Spain, Revenue ($m), 2005-2010 25
Table 12: Fabry's Disease Market, Spain, Forecast ($m), 2010-2018 26
Table 13: Fabry's Disease Market, The UK, Revenue ($m), 2005-2010 27
Table 14: Fabry's Disease Market, The UK, Forecast ($m), 2010-2018 28
Table 15: Fabry's Disease Market, Japan, Revenue ($m), 2005-2010 29
Table 16: Fabry's Disease Market, Japan, Forecast ($m), 2010-2018 30
Table 17: Reduction of GL-3 Inclusions to Normal or Near-normal Levels (0 Score) in the Capillary Endothelium of the Kidney, Heart, and Skin 36
Table 18: Summary of Clinical Trials for Replagal 39
Table 19: Fabry's Disease Therapeutics - Phase III Clinical Pipeline, 2011 40
Table 20: Fabry's Disease Therapeutics - Pre-Clinical and Discovery Pipeline, 2011 40
Table 21: Fabry's Disease, Global, Clinical Trials, 2011 45
Table 22: Fabry's Disease, Global, Clinical Trials by Phase, 2011 46
Table 23: Fabry's Disease, Global, Clinical Trials by Status of Development, 2011 47
Table 24: Fabry's Disease, Global, Overall Sponsors, 2011 48
Table 25: Fabry's Disease, Global, Prominent Sponsors, 2011 49
Table 26: Fabry's Disease, Global, Top Companies by Phase, 2011 50
Table 27: GlaxoSmithKline, Pipeline - 2011 56
Table 28: Amicus, Pipeline - 2011 57
Table 29: Description of Other Companies in the Pipeline, 2011 58
Table 30: Fabry's Disease Therapeutics, Global, Deals, 2011 60
List of Figures
Figure 1: Fabry's Disease - Illustration of Fabry's Disease Timeline 7
Figure 2: Fabry's Disease - Inheritance Pattern 8
Figure 3: Fabry's Disease - Signs and Symptoms 9
Figure 4: Fabry's Disease - Signs and Symptoms 10
Figure 5: Fabry's Disease - Misdiagnosis of Fabry's Disease 11
Figure 6: Fabry's Disease - Clinical Effects on Various Organ Systems 12
Figure 7: Fabry's Disease Therapeutics Market, Global, Revenue ($m), 2005-2010 15
Figure 8: Fabry's Disease Therapeutics Market, Global, Forecast ($m), 2010-2018 16
Figure 9: Fabry's Disease Therapeutics Market, The US, Revenue ($m), 2005-2010 17
Figure 10: Fabry's Disease Therapeutics Market, The US, Forecast ($m), 2010-2018 18
Figure 11: Fabry's Disease Therapeutics Market, France, Revenue ($m), 2005-2010 19
Figure 12: Fabry's Disease Therapeutics Market, France, Forecast ($m), 2010-2018 20
Figure 13: Fabry's Disease Therapeutics Market, Germany , Revenue ($m), 2005-2010 21
Figure 14: Fabry's Disease Therapeutics Market, Germany, Forecast ($m), 2010-2018 22
Figure 15: Fabry's Disease Therapeutics Market, Italy, Revenue ($m), 2005-2010 23
Figure 16: Fabry's Disease Therapeutics Market, Italy, Forecast ($m), 2010-2018 24
Figure 17: Fabry's Disease Therapeutics Market, Spain, Revenue ($m), 2005-2010 25
Figure 18: Fabry's Disease Therapeutics Market, Spain, Forecast ($m), 2010-2018 26
Figure 19: Fabry's Disease Therapeutics Market, The UK, Revenue ($m), 2005-2010 27
Figure 20: Fabry's Disease Therapeutics Market, The UK, Forecast ($m), 2010-2018 28
Figure 21: Fabry's Disease Therapeutics Market, Japan, Revenue ($m), 2005-2010 29
Figure 22: Fabry's Disease Therapeutics Market, Japan, Forecast ($m), 2010-2018 30
Figure 23: Opportunity and Unmet Need in the Fabry's Disease Therapeutics Market, 2011 33
Figure 24: Strategic Competitor Assessment of the Marketed Products in Fabry's Disease Therapeutics, 2011 34
Figure 25: Fabry's Disease Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011 41
Figure 26: Fabry's Disease - Clinical Pipeline by Phase of Development (%), 2011 41
Figure 27: Technology Trends Analytics Framework, 2011 42
Figure 28: Technology Trends Analytics Framework - Description, 2011 42
Figure 29: Fabry's Disease, Global, Clinical Trials by Country, 2011 45
Figure 30: Fabry's Disease, Global, Clinical Trials by Phase (%), 2011 46
Figure 31: Fabry's Disease, Global, Clinical Trials by Status of Development (%), 2011 47
Figure 32: Fabry's Disease, Global, Overall Sponsors (%), 2011 48
Figure 33: Fabry's Disease, Global, Prominent Sponsors (%), 2011 49
Figure 34: Fabry's Disease, Global, Top Companies by Phase, 2011 50
Figure 35: Fabry's Disease Market, Drivers and Barriers, 2011 51
Figure 36: Implications for Future Market Competition in the Fabry's Disease Therapeutics Market, 2011 52
Figure 37: Fabry's Disease Market, Clinical Pipeline by Company, 2011 54
Figure 38: GlobalData Market Forecasting Model 65
Companies mentioned
GlaxoSmithKline
Amicus
To order this report:
Therapy Industry: Fabry's Disease Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article